NKX2-6 and ductal breast carcinoma in situ: The CpGs selected in the test cohort, worked particularly well for the detection of DCIS in the validation cohort; NKX2-6 alone showed a sensitivity of 42% (cut-off methylation 1.3%, 79% specificity) for DCIS detection, which increased to 50% by adding ITIH5 (cut-off 2.9%, 77% specificity).